Tagged with Switzerland

Switzerland Dr René Buholzer, CEO of Interpharma, covers Switzerland’s healthcare advancements, regulatory progress, and the challenges in drug access and digitalization over the past three years. Emphasising collaboration and innovation, Interpharma’s ‘Pharma Strategy 2030’ aims to solidify Switzerland’s leadership in R&D and healthcare sustainability.   Our vision is not just about…

Switzerland The Federal Office of Public Health (FOPH) is the body responsible for safeguarding public health in Switzerland, developing national health policies, and overseeing the Swiss healthcare system. In an exclusive conversation, FOPH Director Anne Lévy discusses the key challenges facing the Swiss healthcare system today and highlights potential solutions as…

Switzerland Thomas Wirth shares insights into Biomed’s strategic focus on the Swiss pharmaceutical market, offering comprehensive services from regulatory support to market access for RX and OTC products. He discusses Biomed’s commitment to long-term partnerships, technological advancements, and driving operational efficiency to stay competitive.   At Biomed, we prioritize delivering value…

Switzerland Hans Peter Borger of Spirig HealthCare discusses the company’s integration with the STADA Group and its focus on generics, consumer healthcare, and specialty markets, including Parkinson’s and rare diseases. He emphasises the importance of a growth mindset and a value-driven culture in navigating Switzerland’s regulatory landscape.   We are committed…

Switzerland Ernst Niemack, managing director of vips, the association representing pharmaceutical companies operating in Switzerland, comments on the government’s latest cost containment measures such as mandatory rebates and new rules for biosimilars and generics, and the impact of these policies on innovative pharma. He also discusses the lag between registrations and…

Switzerland After heading up AstraZeneca Switzerland for one year, Florian Saur reflects on his career journey, discusses the Swiss market and how the country, despite its advanced healthcare and research ecosystem, has fallen behind in terms of access to innovation and digitalization. He shares the ambitious plans to launch 35 new…

Switzerland Swiss Biotech’s Michael Altorfer explains how Switzerland’s biotech industry continues to grow, driven by startups and SMEs and supported by strong international collaborations across the entire value chain. He outlines how Swissmedic’s proactive approach to advanced therapies and participation in the Access Consortium enables faster and more efficient drug approval…

Global AstraZeneca’s Anna Litsiou, Carolyn Hynes and Allison Guy, contributing to the September 2024 edition of DIA’s Global Forum magazine, discuss the importance of improving interactions between health technology assessment (HTA) bodies and regulatory authorities.   The need to optimize drug development and facilitate faster access for patients has focused discussions…

Switzerland Katharina Gasser of Roche Pharma Switzerland lays out her dedication to fostering innovation, strengthening team dynamics, and influencing the future of Switzerland’s healthcare landscape. Gasser emphasizes the need to combat complacency, advance digitalization, and promote diversity in leadership, noting that “complacency is a real threat—it stifles innovation, diminishes drive, and…

Switzerland Christof Kloepper delves into the Basel Area’s positioning as a leading hub for life sciences and biotech innovation. Kloepper emphasizes the region’s commitment to attracting global companies, nurturing startups, and building a strong ecosystem of talent, research, and infrastructure. He draws a comparison to Boston and highlights the Basel Area’s…

Switzerland Dr Stephan Mumenthaler, director of scienceindustries, highlights Switzerland’s strong position in the healthcare, life sciences, and pharmaceutical sectors and explores the nation’s commitment to innovation, sustainability, and maintaining global competitiveness.   Switzerland remains a premier destination for the healthcare, life sciences, and pharmaceutical industries, consistently ranking among the top countries…

Switzerland Switzerland’s healthcare system is at a crossroads. Although still one of the world’s bastions of biopharmaceutical innovation, the country’s domestic healthcare environment is under increasing pressure from rising costs, mounting drug shortages, and a regulatory environment that is slow to adapt. What role could pharmacies and the off-patent industry play…